[Epidemiology of acute bacterial meningitis in adult patients in France].
Identifieur interne : 000497 ( Main/Curation ); précédent : 000496; suivant : 000498[Epidemiology of acute bacterial meningitis in adult patients in France].
Auteurs : E. Varon [France]Source :
- Medecine et maladies infectieuses [ 0399-077X ]
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Amoxicilline (usage thérapeutique), Antibactériens (usage thérapeutique), Enfant (MeSH), France (épidémiologie), Humains (MeSH), Incidence (MeSH), Infections à pneumocoques (épidémiologie), Maladie aigüe (MeSH), Méningite bactérienne (traitement médicamenteux), Méningite bactérienne (épidémiologie), Méningite à méningocoques (traitement médicamenteux), Méningite à méningocoques (épidémiologie), Pénicillines (usage thérapeutique), Résistance bactérienne aux médicaments (MeSH), Sujet âgé (MeSH), Tests de sensibilité microbienne (MeSH).
- MESH :
- traitement médicamenteux : Méningite bactérienne, Méningite à méningocoques.
- usage thérapeutique : Amoxicilline, Antibactériens, Pénicillines.
- épidémiologie : France, Infections à pneumocoques, Méningite bactérienne, Méningite à méningocoques.
- Adolescent, Adulte, Enfant, Humains, Incidence, Maladie aigüe, Résistance bactérienne aux médicaments, Sujet âgé, Tests de sensibilité microbienne.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Acute Disease (MeSH), Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Amoxicillin (therapeutic use), Anti-Bacterial Agents (therapeutic use), Child (MeSH), Drug Resistance, Bacterial (MeSH), France (epidemiology), Humans (MeSH), Incidence (MeSH), Meningitis, Bacterial (drug therapy), Meningitis, Bacterial (epidemiology), Meningitis, Meningococcal (drug therapy), Meningitis, Meningococcal (epidemiology), Microbial Sensitivity Tests (MeSH), Penicillins (therapeutic use), Pneumococcal Infections (epidemiology).
- MESH :
- chemical , therapeutic use : Amoxicillin, Anti-Bacterial Agents, Penicillins.
- geographic , epidemiology : France.
- drug therapy : Meningitis, Bacterial, Meningitis, Meningococcal.
- epidemiology : Meningitis, Bacterial, Meningitis, Meningococcal, Pneumococcal Infections.
- Acute Disease, Adolescent, Adult, Aged, Child, Drug Resistance, Bacterial, Humans, Incidence, Microbial Sensitivity Tests.
Abstract
In 2006, the number of bacterial meningitis cases was estimated at 1375 (2.23/100,000). The leading pathogens involved in adult meningitis were, according to frequency, Streptococcus pneumoniae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus agalactiae, and Haemophilus influenzae. The overall mortality rate averaged 20%, higher among patients with pneumococcal meningitis or in individuals over 65 years of age. Sequels were observed in 30% of cases and more frequent after pneumococcal meningitis. A decrease in susceptibility to antibiotics was reported for N. meningitidis, S. pneumoniae and H. influenzae. Generalized vaccination of children less than two years of age with H. influenzae type b conjugate vaccine has lead to a dramatic decrease in adult H. influenza meningitis. The few cases involved almost exclusively non-typeable strains, presenting in 12% of cases, a modified penicillin binding protein leading to a decreased susceptibility to aminopenicillins. Decreased susceptibility to amoxicillin was observed in 30% of meningococcal isolates, but all strains remained susceptible to parenteral third generation cephalosporins. Resistances to rifampicin or to ciprofloxacin, recommended in meningococcal meningitis prophylaxis, were unusual, but had to be documented. Finally, the proportion of pneumococcal strains with decreased susceptibility to beta-lactams has decreased since 2002. In adult meningitis, pneumococcal isolates with decreased susceptibility to penicillin, amoxicillin, and cefotaxime or ceftriaxone accounted for 37, 18, and 4% of cases respectively. It should be noted that for these isolates, no parenteral third generation cephalosporins MIC was above 2mg/l. Resistance to rifampin was very unusual and all pneumococcal isolates were fully susceptible to glycopeptides.
DOI: 10.1016/j.medmal.2009.02.034
PubMed: 19395209
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000497
Links to Exploration step
pubmed:19395209Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Epidemiology of acute bacterial meningitis in adult patients in France].</title>
<author><name sortKey="Varon, E" sort="Varon, E" uniqKey="Varon E" first="E" last="Varon">E. Varon</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de microbiologie, centre national de référence des pneumocoques, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France. emmanuelle.varon@egp.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de microbiologie, centre national de référence des pneumocoques, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009 Jul-Aug</date>
<idno type="RBID">pubmed:19395209</idno>
<idno type="pmid">19395209</idno>
<idno type="doi">10.1016/j.medmal.2009.02.034</idno>
<idno type="wicri:Area/Main/Corpus">000497</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000497</idno>
<idno type="wicri:Area/Main/Curation">000497</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000497</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Epidemiology of acute bacterial meningitis in adult patients in France].</title>
<author><name sortKey="Varon, E" sort="Varon, E" uniqKey="Varon E" first="E" last="Varon">E. Varon</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de microbiologie, centre national de référence des pneumocoques, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France. emmanuelle.varon@egp.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de microbiologie, centre national de référence des pneumocoques, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Medecine et maladies infectieuses</title>
<idno type="ISSN">0399-077X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Disease (MeSH)</term>
<term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Amoxicillin (therapeutic use)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Child (MeSH)</term>
<term>Drug Resistance, Bacterial (MeSH)</term>
<term>France (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Meningitis, Bacterial (drug therapy)</term>
<term>Meningitis, Bacterial (epidemiology)</term>
<term>Meningitis, Meningococcal (drug therapy)</term>
<term>Meningitis, Meningococcal (epidemiology)</term>
<term>Microbial Sensitivity Tests (MeSH)</term>
<term>Penicillins (therapeutic use)</term>
<term>Pneumococcal Infections (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Amoxicilline (usage thérapeutique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Enfant (MeSH)</term>
<term>France (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Infections à pneumocoques (épidémiologie)</term>
<term>Maladie aigüe (MeSH)</term>
<term>Méningite bactérienne (traitement médicamenteux)</term>
<term>Méningite bactérienne (épidémiologie)</term>
<term>Méningite à méningocoques (traitement médicamenteux)</term>
<term>Méningite à méningocoques (épidémiologie)</term>
<term>Pénicillines (usage thérapeutique)</term>
<term>Résistance bactérienne aux médicaments (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Tests de sensibilité microbienne (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amoxicillin</term>
<term>Anti-Bacterial Agents</term>
<term>Penicillins</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Meningitis, Bacterial</term>
<term>Meningitis, Meningococcal</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Meningitis, Bacterial</term>
<term>Meningitis, Meningococcal</term>
<term>Pneumococcal Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Méningite bactérienne</term>
<term>Méningite à méningocoques</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amoxicilline</term>
<term>Antibactériens</term>
<term>Pénicillines</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term>
<term>Infections à pneumocoques</term>
<term>Méningite bactérienne</term>
<term>Méningite à méningocoques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Acute Disease</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Drug Resistance, Bacterial</term>
<term>Humans</term>
<term>Incidence</term>
<term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Enfant</term>
<term>Humains</term>
<term>Incidence</term>
<term>Maladie aigüe</term>
<term>Résistance bactérienne aux médicaments</term>
<term>Sujet âgé</term>
<term>Tests de sensibilité microbienne</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 2006, the number of bacterial meningitis cases was estimated at 1375 (2.23/100,000). The leading pathogens involved in adult meningitis were, according to frequency, Streptococcus pneumoniae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus agalactiae, and Haemophilus influenzae. The overall mortality rate averaged 20%, higher among patients with pneumococcal meningitis or in individuals over 65 years of age. Sequels were observed in 30% of cases and more frequent after pneumococcal meningitis. A decrease in susceptibility to antibiotics was reported for N. meningitidis, S. pneumoniae and H. influenzae. Generalized vaccination of children less than two years of age with H. influenzae type b conjugate vaccine has lead to a dramatic decrease in adult H. influenza meningitis. The few cases involved almost exclusively non-typeable strains, presenting in 12% of cases, a modified penicillin binding protein leading to a decreased susceptibility to aminopenicillins. Decreased susceptibility to amoxicillin was observed in 30% of meningococcal isolates, but all strains remained susceptible to parenteral third generation cephalosporins. Resistances to rifampicin or to ciprofloxacin, recommended in meningococcal meningitis prophylaxis, were unusual, but had to be documented. Finally, the proportion of pneumococcal strains with decreased susceptibility to beta-lactams has decreased since 2002. In adult meningitis, pneumococcal isolates with decreased susceptibility to penicillin, amoxicillin, and cefotaxime or ceftriaxone accounted for 37, 18, and 4% of cases respectively. It should be noted that for these isolates, no parenteral third generation cephalosporins MIC was above 2mg/l. Resistance to rifampin was very unusual and all pneumococcal isolates were fully susceptible to glycopeptides.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19395209</PMID>
<DateCompleted><Year>2010</Year>
<Month>01</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0399-077X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>39</Volume>
<Issue>7-8</Issue>
<PubDate><MedlineDate>2009 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Medecine et maladies infectieuses</Title>
<ISOAbbreviation>Med Mal Infect</ISOAbbreviation>
</Journal>
<ArticleTitle>[Epidemiology of acute bacterial meningitis in adult patients in France].</ArticleTitle>
<Pagination><MedlinePgn>432-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medmal.2009.02.034</ELocationID>
<Abstract><AbstractText>In 2006, the number of bacterial meningitis cases was estimated at 1375 (2.23/100,000). The leading pathogens involved in adult meningitis were, according to frequency, Streptococcus pneumoniae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus agalactiae, and Haemophilus influenzae. The overall mortality rate averaged 20%, higher among patients with pneumococcal meningitis or in individuals over 65 years of age. Sequels were observed in 30% of cases and more frequent after pneumococcal meningitis. A decrease in susceptibility to antibiotics was reported for N. meningitidis, S. pneumoniae and H. influenzae. Generalized vaccination of children less than two years of age with H. influenzae type b conjugate vaccine has lead to a dramatic decrease in adult H. influenza meningitis. The few cases involved almost exclusively non-typeable strains, presenting in 12% of cases, a modified penicillin binding protein leading to a decreased susceptibility to aminopenicillins. Decreased susceptibility to amoxicillin was observed in 30% of meningococcal isolates, but all strains remained susceptible to parenteral third generation cephalosporins. Resistances to rifampicin or to ciprofloxacin, recommended in meningococcal meningitis prophylaxis, were unusual, but had to be documented. Finally, the proportion of pneumococcal strains with decreased susceptibility to beta-lactams has decreased since 2002. In adult meningitis, pneumococcal isolates with decreased susceptibility to penicillin, amoxicillin, and cefotaxime or ceftriaxone accounted for 37, 18, and 4% of cases respectively. It should be noted that for these isolates, no parenteral third generation cephalosporins MIC was above 2mg/l. Resistance to rifampin was very unusual and all pneumococcal isolates were fully susceptible to glycopeptides.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varon</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratoire de microbiologie, centre national de référence des pneumocoques, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France. emmanuelle.varon@egp.aphp.fr</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Actualisation de l'épidémiologie des méningites bactériennes aiguës chez l'adulte en France.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>04</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Med Mal Infect</MedlineTA>
<NlmUniqueID>0311416</NlmUniqueID>
<ISSNLinking>0399-077X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010406">Penicillins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>804826J2HU</RegistryNumber>
<NameOfSubstance UI="D000658">Amoxicillin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000658" MajorTopicYN="N">Amoxicillin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016920" MajorTopicYN="N">Meningitis, Bacterial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008585" MajorTopicYN="N">Meningitis, Meningococcal</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010406" MajorTopicYN="N">Penicillins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011008" MajorTopicYN="N">Pneumococcal Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>01</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>02</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19395209</ArticleId>
<ArticleId IdType="pii">S0399-077X(09)00095-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.medmal.2009.02.034</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000497 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000497 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= GrippeFranceV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:19395209 |texte= [Epidemiology of acute bacterial meningitis in adult patients in France]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:19395209" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a GrippeFranceV1
![]() | This area was generated with Dilib version V0.6.35. | ![]() |